International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols

Cancer

Volumn 117, Issue 5, 2011, Pages 1001-1009

  Waheed, Sarah ^a   Shaughnessy, John D ^a   Van Rhee, Frits ^a   Alsayed, Yazan ^a   Nair, Bijay ^a   Anaissie, Elias ^a   Szymonifka, Jackie ^a   Hoering, Antje ^b   Crowley, John ^b   Barlogie, Bart ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Cytogenetic abnormalities; Gene expression profiling; International staging system; Myeloma; Prognosis

Indexed keywords

BORTEZOMIB; MELPHALAN; THALIDOMIDE;

AGED; ARTICLE; CANCER STAGING; CHROMOSOME ABERRATION; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOGENETICS; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME ABERRATIONS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DATA INTERPRETATION, STATISTICAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; METAPHASE; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; THALIDOMIDE;

EID: 79952034869     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25535     Document Type: Article

References (16)

1. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021-1030. (Pubitemid 43357806)
2. Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007;138:176-185. (Pubitemid 46978271)
3. Shaughnessy J, Zhan F, Burington B, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276-2284. (Pubitemid 46425864)
4. Greipp P, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-3420.
5. Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol. 2008;140:625-634. (Pubitemid 351300910)
6. Jacobson J, Barlogie B, Shaughnessy J, et al. MDS-type abnormalities with myeloma signature karyotype (MMMDS). Only 13% 1-year survival despite tandem transplants. Br J Haematol. 2003;122:430-440. (Pubitemid 36951627)
7. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020-2028. (Pubitemid 44395016)
8. Nair B, Shaughnessy JD, Zhou Y, et al. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. Blood. 2009;113:6572-6575.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481..
10. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bull. 1945;1:80-83.
11. Cox DR. Regression models and life-tables. J R Stat Soc [B]. 1972;34:187-202.
12. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23:2210-2221.
13. Avet-Loiseau H, Li C, Magrangeas F, et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol. 2009;27:4585-4590.
14. Pineda-Roman M, Zangari M, van Rhee F, et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia. 2008;22:1419-1427. (Pubitemid 352006086)
15. Shaughnessy JD, Zhou Y, Haessler J, et al. TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. Br J Haematol. 2009;147:347-351.
16. Nair B, van Rhee F, Shaughnessy JD, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with bortezomib, lenalidomide and dexamethasone (VRD) maintenance. Blood. 2010;115:4168-4173.